Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

When it comes to cracking the U.S. healthcare reimbursement nut, even the most cunning of diagnostics outfits need a decent dose of patience, persistence and perhaps a prayer or two. Melbourne’s Lumos Diagnostics (ASX: LDX), purveyor of the rapid test darling FebriDx®, has just inched closer to the Promised Land — with a pair of Medicare wins that could open the floodgates for wider adoption of its ten-minute sniffle sorter.

Now, for the uninitiated, FebriDx is a clever little tool designed to tell the difference between bacterial and non-bacterial respiratory infections — the kind of call that determines whether your local GP reaches for antibiotics or not. It does so with a simple finger prick and within 10 minutes, giving it the kind of edge that’s catnip to emergency departments and primary care clinicians alike.

But having a test that works is only half the battle. In the Byzantine world of U.S. healthcare, getting paid is the real sport. And that’s where Lumos has just landed a couple of critical goals.

The company has secured reimbursement coverage from two of the seven Medicare Administrative Contractors (MACs) — Palmetto and Novitas — at the modest but respectable rate of US$41.38 a pop, effective April 2025. It’s a technical milestone, but one with big commercial implications.

Why? Because these MACs act as gatekeepers for Medicare, the U.S. government’s health safety net that covers about 20% to 24% of all test reimbursements. And more often than not, what Medicare covers, the private insurers — who pick up the tab for the rest — eventually follow.

To rewind slightly, FebriDx had already nabbed a spot on the 2025 Clinical Laboratory Fee Schedule via the somewhat unromantic-sounding PLA Code #0442U, thanks to the Centres for Medicare & Medicaid Services (CMS). That established a nationwide reimbursement rate, but didn’t guarantee anyone would actually get paid.

As Lumos boss Doug Ward put it, “It is extremely pleasing to achieve some early wins with two of the 7 U.S. Medicare Administration Contractors. This is an important and critical step in building the reimbursement framework to support clinical adoption for FebriDx®.”

Indeed, Doug. While those two wins won’t yet buy a private island, they’re the kind of beachhead that matters in the slow grind of healthcare monetisation. Negotiations are said to be “well progressed” with another three MACs — Noridian, WPS, and CGS — which, if landed, would mean Lumos has five of the seven in its pocket.

This isn't just about bureaucracy; it’s about building momentum. As real-world usage picks up, and clinicians begin seeing value in the test — both diagnostically and economically — insurers become more inclined to cover it. Lumos’ field teams are already doing the legwork, helping with insurance appeals, collecting clinician feedback, and documenting medical necessity.

There’s a kicker too. FebriDx is already cleared for both Moderately Complex and CLIA-Waived environments (those are U.S. regulatory categories for test complexity, not dodgy Sicilian resorts). Should Lumos secure a CLIA waiver, the test could shift more fluidly between healthcare settings without starting the reimbursement song and dance all over again.

Now, this isn't Lumos' first rodeo with FebriDx. The company has been on a long road with the product, having had previous bumps including regulatory hurdles and funding squeezes. But it’s now finding its stride, with this reimbursement progress acting as both validation and a commercial accelerant.

And lest we forget, the test is manufactured in the U.S., a patriotic plus that’s bound to sit well with lawmakers and job-conscious decision-makers in D.C.

The share market hasn’t exactly gone gaga over Lumos of late, but news like this could offer a flicker of light for investors seeking under-the-radar medtech plays with tangible catalysts on the horizon.

As is always the case in diagnostics land, success isn’t measured in test performance alone. It’s the bureaucratic dominoes that need to fall — and Lumos has just nudged two of them.

Now it’s a question of how fast the rest tumble.

In a move that might have been met with a shrug on the ASX boards this morning, but deserves a double take, Kiwi-Aussie medtech outfit TruScreen (ASX/NZX: TRU) has inked a significant public health pact in Vietnam. The initiative will see the company’s AI-powered cervical cancer screening device deployed across Ho Chi Minh City in a five-year push to screen 260,000 women—a scale that dwarfs anything in the company’s history.

It’s not every day that a small-cap straddling the ditch muscles into one of Southeast Asia’s most pressing health challenges. But that’s exactly what TruScreen’s done. The company has teamed up with the Ho Chi Minh City Public Health Association (HPHA) and its local distributor, Gorton Health Services, to tackle the country’s dismal cervical cancer screening rate, which sits at a mere 25% of the targeted demographic. The Vietnamese government’s goal? Hit 60% of women aged 30 to 54—a cohort that numbers in the tens of millions.

The official rollout began on 12 April with a ceremony attended by not just public health luminaries but also reps from the Australian Consulate and the Vietnam Cancer Association—illustrating just how seriously the effort is being taken. The device of choice is TruScreen’s own Ultra®, a portable, AI-enabled, real-time screening tool that does away with labs, pathologists, and the usual cytology rigmarole. It’s screening on the fly, no slides or stains required.

As TruScreen Chair Tony Ho, alongside HPHA president Dr Le Truong Jiang and GHS Vietnam CEO Mr Tran An Bao, put ink to paper, CEO Marty Dillon didn’t mince words on the mission’s stakes: “This program… may save the lives of over 2,600 mothers, daughters, sisters, wives and friends.”

It’s also a milestone for the company’s long-haul efforts in Vietnam. TruScreen’s technology was only added to the Vietnamese Ministry of Health’s official playbook in December 2023. Now it’s front and centre in one of the largest urban population centres in the region.

The broader Vietnamese market is tantalising. The country has 36 million women aged 18 to 65—TruScreen’s entire addressable demographic. Ho Chi Minh City, with 9 million people, is a launchpad. If all goes well, the model will be replicated across the nation and potentially across Southeast Asia. The company is already touting the program as a “reference site for neighbouring countries”.

Operationally, the plan is as meticulous as it is ambitious. Social workers will go door-to-door educating women and signing them up. The actual screenings will happen at district health centres and private clinics, supported by three major hospitals: Tu Du, Hung Vuong, and Ung Buou. Even the Ho Chi Minh City Women’s Union is lending a hand on the media front. It’s a full-court press.

From an investment angle, it’s worth noting that TruScreen is still far from blue-chip territory. But this partnership gives it something it has long lacked—scale and validation. For a medtech that has long spruiked its ability to leapfrog traditional screening methods in low- and middle-income countries, this is not just a commercial win but a proof of concept.

The device itself, TruScreen Ultra®, has a CE Mark, is TGA registered in Australia, and is already in use in 29 countries, including China, Russia, Mexico and Zimbabwe. In FY24 alone, over 200,000 tests were performed using the device—mostly on the back of single-use sensor sales. Now, with the 260,000-screening goal in Ho Chi Minh City alone, that annual figure could look modest.

What sets TruScreen apart is its tech’s agility. Unlike Pap smears or HPV tests which require samples, labs and follow-ups, TruScreen’s gizmo gives results on the spot using low-level optical and electrical stimuli. In a place where lab infrastructure is patchy and awareness about cervical cancer is low, that’s a genuine advantage.

And while the market hasn’t popped champagne on the news yet, this development should be watched closely. A successful run in Vietnam could open doors not just in ASEAN but also in public health procurement circles globally. For a small-cap often flying under the radar, this could be the announcement that finally puts it on the map.

As Dillon puts it, “This program… increases screening uptake amongst the women of Ho Chi Minh City.” It may also do the same for investor interest in TruScreen.

Anatara Lifesciences (ASX: ANR) has delivered the headline results from Stage 2 of its much-anticipated Phase II GaRP-IBS trial—and the outcome is a classic case of “glass half full” for investors and clinicians alike. While the trial failed to meet its primary efficacy endpoint of statistically significant symptom reduction in Irritable Bowel Syndrome (IBS) compared to placebo, the data paint a more nuanced picture, with secondary outcomes offering genuine reasons for cautious optimism.

Let’s address the gut-wrenching news first: the primary endpoint, a reduction in the IBS Symptom Severity Score (IBS-SSS), did not achieve statistical significance. The placebo cohort, true to type in IBS trials, showed a robust early response, with a convergence of scores between placebo and the GaRP treatment group by week 8. Despite this, those on GaRP recorded a consistent and sustained improvement, with a 45% reduction in symptoms—an outcome that, while clinically meaningful, didn’t cross the magic p-value threshold.

Executive Chair Dr David Brookes was candid: “Not reaching significance for the primary efficacy endpoint in any quality trial has to be a real disappointment... however the trial has still delivered significant findings.” Indeed, the silver linings start to emerge in the secondary endpoints, particularly the statistically significant improvement in anxiety scores (p=0.034 at week 8), contributing to a significant overall HADS (Hospital Anxiety and Depression Scale) improvement (p=0.025).

This is not just statistical hair-splitting. Anxiety is a well-recognised co-morbidity in IBS, and the gut-brain axis is increasingly seen as a legitimate therapeutic target. A reduction in anxiety without affecting depression (which remained in the normal range) points to a subtle but valuable benefit, potentially reflecting the microbiome-modulating properties of the GaRP formulation.

Even more telling is the result for the “Adequate Relief” metric—essentially a patient-reported perception of symptom improvement—which was highly significant at week 10 (p=0.004). In plain terms, more patients felt better on GaRP than placebo, and that feeling persisted two weeks after stopping the treatment. That’s a strong endorsement for a product aimed at a condition with few clear-cut treatment wins.

The modified intent-to-treat (ITT) analysis reinforced these findings, with GaRP delivering a 115-point reduction in IBS-SSS from baseline, compared to 80 for placebo. While not statistically definitive, the clinical impact—particularly in a population suffering moderate IBS—shouldn’t be dismissed.

On the strategic front, Anatara is now at a crossroads. The disappointment of missing the primary endpoint will inevitably cool some partnering enthusiasm sparked by Stage 1’s strong results, but the overall package—solid safety profile, clinically meaningful benefits, and signals of a gut-brain effect—remains intact.

Commercialisation paths are still on the table, with Anatara working to package its preclinical and clinical findings into a format more palatable for prospective partners. The GaRP product, composed of GRAS (Generally Regarded As Safe) ingredients, remains protected under current patent filings, and management is eyeing broader indications, possibly even within the nebulous but growing gut-brain health category.

Meanwhile, the anti-obesity project ticks along quietly in the background. Proof-of-concept studies are underway in mice at the University of Newcastle, exploring GLP-1 agonist-like effects using novel oral compounds. The company has allocated $250,000 to the initial studies, which are expected to yield results within six months. While early-stage and still under wraps, the obesity program could provide Anatara with a fresh commercial avenue, especially given current market enthusiasm around GLP-1s.

With its coffers buoyed by a $500,000 R&D tax rebate and operational costs trimmed (including a shift to part-time roles and non-executive board positions), Anatara is consolidating rather than retreating. Manufacturing and ingredient sourcing for GaRP are now on the back burner, with resources focused on data consolidation and strategic reorientation.

In summary, while the GaRP-IBS trial didn’t deliver a slam-dunk, it certainly hasn’t flatlined. The data offer tantalising hints of clinical relevance in a notoriously difficult therapeutic area. For investors and potential partners, it’s not a matter of if GaRP works—but how best to interpret and capitalise on the signals that it might.

Memphasys (ASX: MEM), the reproductive biotech based in Sydney’s inner west, is on the move again—this time with a fresh $1.275 million in hand, raised via a strategic placement to both new and loyal shareholders. The funds arrive at a pivotal moment, just weeks after the company’s flagship product, the Felix™ System, emerged from a critical clinical trial with top marks.

Let’s be clear on what Felix is—and why investors are paying attention.

Felix™ is the world’s first sperm separation device using electrophoresis. It’s designed for use in Assisted Reproductive Technology (ART) procedures, such as IVF. Unlike traditional methods like Swim-Up and Density Gradient Centrifugation (DGC), which rely on centrifugation or manual layering, Felix uses an electrical charge and a size-exclusion membrane to gently and quickly isolate the healthiest, most motile sperm.

In practice, this means embryologists can achieve more consistent results with less hands-on time, a big plus for fertility clinics trying to streamline their workflows while optimising success rates. And the clinical data now backs it up.

In late March, Memphasys reported results from a pivotal trial conducted with Monash IVF. Felix was found to be just as effective as the Swim-Up method (the trial’s primary endpoint) and statistically superior to DGC—the most commonly used sperm prep method worldwide. Even better, not a single adverse event was reported. Time-wise, Felix was also faster than both legacy techniques, and it won over embryology staff: 100% preferred it to DGC, and more than half favoured it over Swim-Up.

CEO Dr David Ali called it a “defining moment” for the company, and you can see why. With the technology now clinically validated, Memphasys is no longer pushing a promise—it’s got a proven performer on its hands.

The commercial implications are significant.

With the trial box ticked, the company is now preparing regulatory submissions to the CE Mark (Europe), TGA (Australia), and CDSCO (India). These approvals will open doors to some of the largest ART markets globally, including mutual recognition pathways in countries like Japan, Canada, the US, and Switzerland.

There’s already groundwork laid. Distribution agreements with Vitrolife are in place for Japan, Canada, and New Zealand. A letter of intent exists with Heranova in China, and R&D sales have begun in the UAE. Vitrolife, in particular, has been running real-world utilisation testing in Japan for over a year—and had been waiting for clinical data before ramping up sales. Now that data is on the table, the pathway to commercial traction is looking a lot clearer.

The placement—priced at $0.006 per share with free-attaching options exercisable at $0.011—was conducted under the company’s existing ASX capacity, meaning no shareholder approval was needed. It drew strong participation from both new and existing backers, a reflection of growing belief in Memphasys’ commercial strategy.

The funds will be used to support regulatory submissions, advance commercial discussions (including potential joint ventures), and continue the rollout of both Felix and the RoXsta™ platform. RoXsta, while earlier in its journey, is showing potential in livestock applications such as bull fertility and mastitis detection in dairy cattle.

But make no mistake—Felix is the main act. With validation secured and strategic partners in place, Memphasys is now gearing up to transform a once-promising prototype into a globally marketed fertility solution. For investors, the question isn’t whether Felix works—it’s how quickly Memphasys can convert interest into income. And with the company now cashed-up and clinically armed, the countdown is on.

Amidst the growing global anxiety around critical minerals supply, MTM Critical Minerals (ASX: MTM) is quietly putting together one of the more compelling transformation stories on the ASX. This week’s investor webinar provided an update on its innovative metal recovery technology — and more tellingly, it introduced a man whose pedigree could be the clincher for institutional credibility: Steve Ragiel.

Ragiel, the President and Managing Director of FlashMetals USA, has over three decades of frontline experience in the global recycling industry. As he explained during the presentation, “I’ve run billion-dollar recycling businesses, but I haven’t seen a technology as disruptive as this one.”

He’s not exaggerating. Ragiel’s resume includes stewardship of Waste Management Inc’s (NYSE: WM) US$1 billion-a-year recycling operation, which included over 80 sites across the United States. He also spent five years leading international expansion, working across Europe and importing high-performance recycling technologies back to North America.

“I’ve been CEO of several private equity-backed ventures with successful exits,” Ragiel noted. “What attracted me to MTM was not just the technology, but the speed and capital efficiency. We can build smaller, smarter, faster – and the margins are unlike anything I’ve seen in e-waste.”

Flash Heating Meets Flash Leadership

MTM’s technology, Flash Joule Heating (FJH), was born in a Rice University lab and designed originally to produce graphene from plastic waste. MTM’s pivot — to use the same rapid electric pulse process to liberate metals from e-waste and mineral feedstocks — is the kind of intellectual leap that tends to create entire industries.

But tech alone doesn’t commercialise itself. That’s where Ragiel steps in.

According to CEO Michael Walsh, Ragiel has been instrumental in securing MTM’s first two binding feedstock supply deals — not easy wins, considering these are two of the largest U.S. recycling companies in the sector. “It’s really down to Steve’s industry relationships. Some of these go back 20 years,” said Walsh.

The deals cover over 1,100 tonnes per annum of high-grade e-waste, rich in gold, copper, indium, tin and other technology metals — material that, thanks to conventional smelters’ stranglehold, has historically been sold at a fraction of its true value. Ragiel is rewriting that script.

“These recyclers are frustrated,” he said. “They send their scrap to smelters in Asia, wait months to be paid, and get no transparency about what’s actually recovered. We’re offering higher payments, faster turnaround, and full data visibility on the assays. It’s a game-changer.”

Commercial Strategy: Built for Speed, Not Scale

MTM’s business model is split into two streams: a “build-own-operate” approach for urban mining (e-waste, refinery waste) and a licensing model for larger-volume mineral processing applications such as red mud and spodumene.

For Ragiel, the key commercial insight lies in the modularity. “With this tech, you don’t need to build a billion-dollar plant to be viable. A one-tonne-per-day line can be built fast and generate serious margins. And if you need more throughput? Add another reactor.”

MTM expects to begin building its first U.S. demo facility in Houston, Texas by August or September. Initial production is targeted for December, with commercial sales expected in H1 2026 — a rapid timeline made possible by selecting brownfield industrial sites with existing infrastructure.

The Numbers That Matter

From a financial perspective, the economics of MTM’s feedstock are eye-popping. One tonne of gallium-germanium refinery waste from Indium Corporation, for example, could contain up to $1 million worth of metal at spot prices. Meanwhile, a recently tested e-waste sample contained 550 grams of gold per tonne — significantly higher than most gold ore bodies.

Importantly, MTM doesn’t just expect to recover these metals — it’s producing them as chlorides, which in many cases command higher prices than the metal itself due to purity and downstream applicability.

“That’s a big differentiator,” Ragiel noted. “If the end-user wants germanium chloride, and we can produce that directly — we’re saving them a processing step. That has real economic value.”

He’s also keen to highlight the “hedged” nature of MTM’s business model. Because MTM pays for e-waste based on contained metal content (via assay), it avoids the speculative exposure of most commodity plays. As prices fall, feedstock gets cheaper. If prices rise, margins expand. Either way, the spread is locked in.

A Hedge Against Tariff Turmoil

The geopolitical backdrop is another tailwind. With tariffs on Chinese-sourced metals hitting 145% and China banning exports of gallium and germanium, U.S. recyclers are scrambling for domestic solutions. MTM’s timing couldn’t be better.

“Everything we’re doing is aligned with U.S. onshoring strategy,” Walsh said. “We’re in talks with the Department of Defense, we’ve applied for DoD and DoE grants, and we’re building domestic capacity to process critical metals. It’s a win-win.”

The company is also engaged with Vedanta, India’s largest aluminium producer, on red mud recycling. With over 20% alumina and 7% titanium locked in this notoriously stubborn waste stream, MTM’s ability to unlock that value — and convert the residue into green cement feedstock — could offer another major revenue vertical.

Funding and Forward Momentum

MTM is currently sitting on over $10 million in cash and does not anticipate a near-term capital raise. About 25% of the demo plant’s capex has already been spent on engineering and long-lead items.

Ragiel is bullish. “We’re capital light, operationally lean, and running at full clip toward revenue. I’ve seen a lot of recycling tech in my time, but this is the first one I’ve wanted to bet my career on.”

It’s a bold call — but one that might just make MTM worth a closer look. In a sector dominated by slow-moving incumbents and geopolitical chokepoints, the combination of deep tech and deep industry experience could be just what’s needed to shake things up. Investors won’t have to wait long to see if Ragiel and Walsh can turn metal from waste — and promise into profit.